How Much Does Belsomra (Suvorexant) Cost in Wisconsin in 2026?

Retail and Cash-Pay Pricing Across Wisconsin

The average cash-pay price for a 30-day supply of Belsomra at Wisconsin retail pharmacies sits near $85 per month when patients use pharmacy discount programs or negotiated cash rates. Without any discount, the wholesale acquisition cost (WAC) set by Merck is $340 per month. That gap matters. Patients paying sticker price overpay by roughly 75%.

Pricing varies by pharmacy chain and location within Wisconsin. Costco, Walmart, and independent pharmacies in Milwaukee, Madison, and Green Bay each set different dispensing fees and markups. Patients should compare prices at multiple pharmacies using verified discount tools before filling a prescription. The FDA-approved labeling for Belsomra specifies four dose strengths (5 mg, 10 mg, 15 mg, and 20 mg), and pricing is typically uniform across strengths for the brand product 1.

No FDA-approved generic suvorexant exists as of May 2026. Merck holds patent protections that have kept generic manufacturers from entering the market. Until generic competition arrives, discount programs and insurance remain the primary tools for reducing out-of-pocket cost. The AASM clinical practice guideline for chronic insomnia lists suvorexant among recommended pharmacologic options, reinforcing its clinical value despite the higher brand-only price point 2.

Wisconsin ranks in the middle tier nationally for prescription drug costs. State-level data from the Wisconsin Office of the Commissioner of Insurance shows that insured patients with tiered formularies typically encounter Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing copays between $40 and $75 per month depending on the plan 3.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service programs) covers Belsomra, but only with prior authorization. The PA requirement means prescribers must document that the patient has tried and failed, or has a contraindication to, at least one preferred sleep agent before Medicaid will approve suvorexant.

Preferred alternatives on the Wisconsin Medicaid preferred drug list typically include generic zolpidem, trazodone, and generic eszopiclone. Prescribers submit the PA request through the Wisconsin Medicaid pharmacy benefit manager, and approvals generally come within 24 to 72 hours. The FDA label recommends starting suvorexant at 10 mg nightly, with a maximum dose of 20 mg, and the PA criteria usually align with these dosing parameters 1.

For patients enrolled in Wisconsin Medicaid managed care organizations (MCOs) such as Quartz, Molina, or Dean Health Plan, the PA criteria may differ slightly from fee-for-service. Each MCO maintains its own formulary, though all must cover at least one dual orexin receptor antagonist (DORA). Patients denied coverage can file a Medicaid fair hearing appeal through the Wisconsin Department of Health Services 4.

The clinical rationale supporting Medicaid coverage rests on strong trial data. In the registration trial by Herring et al. (2014, N=250 in the primary efficacy population), suvorexant significantly improved subjective total sleep time and wake after sleep onset versus placebo over four weeks 5. A longer 12-month safety and efficacy study confirmed that benefits persisted without evidence of rebound insomnia on discontinuation 6.

Commercial Insurance and Formulary Placement in Wisconsin

Major commercial insurers operating in Wisconsin, including UnitedHealthcare, Anthem Blue Cross Blue Shield, Quartz, and Group Health Cooperative of South Central Wisconsin, each make independent formulary decisions about Belsomra. Most place it on Tier 3 or Tier 4. Some plans require step therapy through generic zolpidem or trazodone before approving suvorexant.

Patients with employer-sponsored insurance in Wisconsin typically face copays of $40 to $75 per month for Tier 3 drugs. For plans that place Belsomra on Tier 4 (non-preferred brand) or specialty tier, coinsurance models may apply, meaning the patient pays a percentage of the drug cost rather than a flat copay. A 25% coinsurance rate on the $340 list price yields $85 out of pocket, which aligns with the average cash-pay price and offers no financial advantage over discount programs 7.

Medicare Part D enrollees in Wisconsin face similar formulary hurdles. Most Part D plans cover suvorexant but apply quantity limits (30 tablets per 30 days) and may require prior authorization. During the coverage gap ("donut hole"), Medicare beneficiaries pay 25% of the negotiated price for brand drugs. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully in effect for 2026, helps limit total yearly exposure for patients taking multiple brand medications 8.

For patients whose plans deny coverage outright, the appeals process starts with a coverage determination request from the prescriber, followed by an internal appeal, and if needed, an external review through Wisconsin's Office of the Commissioner of Insurance.

Merck Savings Card and Patient Assistance

Merck offers a co-pay savings card for Belsomra that can reduce the out-of-pocket cost to $0 for eligible commercially insured patients. The card covers the difference between the patient's copay and the program floor, up to a specified annual maximum. Eligibility requirements exclude patients with government insurance (Medicare, Medicaid, Tricare, VA).

Wisconsin residents with commercial insurance can activate the Merck savings card online or through their prescriber's office. The card works at all major retail pharmacies across Wisconsin, including Walgreens, CVS, Pick 'n Save pharmacy, and Walmart. Patients should present both their insurance card and the savings card at the pharmacy counter.

For uninsured patients or those who do not qualify for the savings card, Merck's patient assistance program (Merck Helps) provides Belsomra at no cost to individuals meeting income criteria, generally set at or below 400% of the federal poverty level. Applications require documentation of income and a prescription from a licensed provider 9.

The American Academy of Sleep Medicine (AASM) notes that cost barriers contribute to medication nonadherence in insomnia treatment, which can worsen comorbid conditions including depression, cardiovascular disease, and metabolic dysfunction 10. Financial assistance programs directly address this barrier.

Compounded Suvorexant in Wisconsin: Legality and Access

Compounded suvorexant is available through licensed 503A compounding pharmacies in Wisconsin. Under federal law (the Drug Quality and Security Act, DQSA), 503A pharmacies may compound patient-specific prescriptions when a prescriber determines that a commercially available product does not meet an individual patient's needs, such as requiring a non-standard dose or a different dosage form 11.

Wisconsin's Pharmacy Examining Board, which operates under the Department of Safety and Professional Services, regulates in-state compounding pharmacies. A 503A pharmacy in Wisconsin must hold a valid state license and comply with USP standards for non-sterile or sterile compounding as applicable. Suvorexant is a Schedule IV controlled substance, so compounding pharmacies must also maintain DEA registration and comply with all controlled substance record-keeping requirements 12.

The cost of compounded suvorexant in Wisconsin can be significantly lower than brand Belsomra. Some 503A pharmacies offer compounded formulations for under $40 per month. Patients should verify that the pharmacy holds current Wisconsin licensure and that the prescriber has provided a valid patient-specific prescription. Compounded drugs are not FDA-approved and do not undergo the same regulatory review as manufactured products. The FDA has issued guidance cautioning that compounded drugs carry additional risks related to potency, sterility, and purity 13.

Telehealth Prescribing of Belsomra in Wisconsin

Wisconsin permits telehealth prescribing of suvorexant. The state's telehealth parity law (Wis. Stat. § 253.06 and related administrative code) allows licensed prescribers to evaluate insomnia patients and prescribe Schedule IV controlled substances via audio-video telehealth visits. A valid prescriber-patient relationship must be established, which in Wisconsin can occur through a real-time telehealth encounter.

DEA regulations for telehealth prescribing of controlled substances were updated under the SUPPORT Act and subsequent rulemaking. As of 2026, prescribers may initiate a Schedule IV prescription via telehealth without a prior in-person evaluation, provided the encounter meets DEA and state-specific requirements 14. Wisconsin does not impose additional restrictions beyond federal requirements for Schedule IV telehealth prescribing.

For Wisconsin residents in rural areas, where access to sleep medicine specialists may require driving over an hour, telehealth prescribing removes a significant access barrier. The Wisconsin Collaborative for Healthcare Quality has documented that telehealth utilization for behavioral health and sleep disorders increased by over 300% between 2019 and 2023, with sustained adoption levels through 2026 15.

Patients using telehealth to obtain a Belsomra prescription can fill it at any licensed Wisconsin pharmacy. The electronic prescription is transmitted directly from the telehealth provider to the patient's preferred pharmacy, and all standard insurance and discount card options apply.

How Suvorexant Compares to Other Sleep Medications on Cost

Suvorexant is one of three FDA-approved dual orexin receptor antagonists (DORAs), alongside lemborexant (Dayvigo) and a third DORA approved more recently. Among these, suvorexant and lemborexant both remain brand-only products in 2026, with similar pricing. Lemborexant carries a list price near $380 per month, making it slightly more expensive than Belsomra at the WAC level 16.

Generic alternatives in different drug classes offer dramatically lower costs. Zolpidem (generic Ambien) is available for $5 to $15 per month at most Wisconsin pharmacies. Generic trazodone, used off-label for insomnia, costs under $10 per month. Generic eszopiclone (generic Lunesta) runs $15 to $30 per month. These price differences explain why insurers and Medicaid require step therapy through generics before approving DORAs.

The clinical differentiation between DORAs and older sleep agents matters for cost-effectiveness analysis. DORAs work by blocking orexin-mediated wakefulness rather than broadly suppressing CNS activity, which produces a different safety profile. In a meta-analysis by Kishi et al. (2015), suvorexant demonstrated efficacy for sleep onset and maintenance insomnia with a lower risk of next-day residual sedation compared to benzodiazepine receptor agonists 17. The Herring et al. trial showed suvorexant 20 mg improved subjective total sleep time by 20.8 minutes over placebo (P<0.001) at month one, with sustained benefit at three months 5.

For patients who have failed or cannot tolerate generic options, the added cost of suvorexant may be clinically justified. Cognitive behavioral therapy for insomnia (CBT-I) remains the AASM first-line recommendation and carries no ongoing medication cost, though access to trained CBT-I providers in Wisconsin remains limited outside Milwaukee and Madison 18.

Safety Considerations That Affect Cost Decisions

Cost should not be the sole factor driving medication selection for insomnia. Suvorexant's controlled-substance scheduling (Schedule IV) reflects a lower abuse potential than Schedule II or III drugs, and clinical trial data support this classification. In abuse-liability studies, suvorexant showed subjective "drug liking" scores lower than zolpidem at equivalent therapeutic doses 19.

Common adverse effects include somnolence (7% vs. 3% placebo), headache, and dizziness. The FDA label carries a boxed warning about CNS-depressant effects and risk of impaired next-morning driving, particularly at the 20 mg dose. Patients should not take suvorexant unless they can dedicate at least 7 hours to sleep 1.

The Endocrine Society clinical practice guideline on sleep and metabolic health notes that untreated chronic insomnia increases risk of type 2 diabetes, hypertension, and obesity, conditions that generate far greater healthcare costs than the price of a sleep medication 20. A Wisconsin patient paying $85 per month for Belsomra spends $1,020 per year, a fraction of the average annual cost of managing newly diagnosed type 2 diabetes ($9,601 per the ADA's 2023 cost-of-diabetes analysis) 21.

Prescribers in Wisconsin should document the clinical rationale for choosing suvorexant over generics, as this documentation supports both insurance appeals and prior authorization requests. Starting at the 10 mg dose and titrating to 20 mg only if needed aligns with FDA labeling and minimizes cost for patients paying per-tablet pricing.